Antiplatelet drugs
Clinical effects of antiplatelet drugs and statins on D-dimer levels
... let drugs and/or statins on D-dimer levels was taken into ...reclassify antiplatelet drugs and/or statin users by adjusting the D- dimer ...of antiplatelet drugs and/or statin users in ...
8
THE SUCCESS OF DIFFERENT APPROACHES TO THE DEVELOPMENT TO ANTIPLATELET DRUGS
... Platelet aggregation can be quantified by recording the transmission of a light beam across a suspension of continually disturbed platelets in an aggregometer 20 . Optical aggregometry caused the finding of the first ...
9
PRESCRIPTION PATTERN OF ANTIHYPERLIPIDEMIC AND ANTIPLATELET DRUGS IN THE MANAGEMENT OF CORONARY ARTERY DISEASE IN A TERTIARY CARE HOSPITAL
... and antiplatelet drugs within the administration of coronary course illness and to create Medicine prescribing observing practice which serves as an apparatus for evaluating the endorsing, apportioning and ...
10
Development of a perfusion chamber assay to study in real time the kinetics of thrombosis and the antithrombotic characteristics of antiplatelet drugs
... Coupling the real time feature of intravital technology with perfusion chamber has been proposed by the group of McIntire almost 20 years ago [4]. This concept was based on the simple idea that real time monitoring of ...
11
Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE AF): study protocol for a randomised controlled trial
... antithrombotic drugs, a recent ICH is a relative contra-indication to their use and current clinical evi- dence on this topic is scarce or ...thrombotic drugs are all strategies used by clinicians ...
12
TRIPLE ANTIPLATELET THERAPY AND INCIDANCE OF DRUG RESISTANCE
... to antiplatelet drugs is associated with subsequent major adverse clinical ...triple antiplatelet therapy in comparison of dual antiplatelet ...cilostazol) antiplatelet therapy or ...
9
Perioperative antiplatelet in elderly patients aged over 70 years treated with proximal femur fracture: continue or discontinue?
... discontinue antiplatelet drugs at admis- sion and restart postoperatively, or continue antiplatelets perioperatively in elderly patients with hip ...
7
Combination of Oral Anticoagulant with Antiplatelet and All-cause Mortality in Elderly Patients with Atrial Fibrillation and Ischemic Heart Disease
... than antiplatelet drugs in reducing the risk of thromboembolic events associated with AF ...[3]. Antiplatelet agents are preferred in patients with IHD as well as those receiving percutaneous ...
9
Effect of Antiplatelet Therapy on Thromboembolic Complications of Elective Coil Embolization of Cerebral Aneurysms
... of the first framing coil detached within the aneurysm, because fram- ing coils detached were consistently documented in procedure re- ports, but measurements of aneurysm diameters were not. The rela- tionship of ...
5
Antiplatelet combinations for prevention of atherothrombotic events
... fixed-dose antiplatelet drugs may be used in a wide spectrum of patients moving towards superior patient adherence, relevant especially in high-risk cardiovascular patients (eg, following coronary ...
8
Prevention of the renarrowing of coronary arteries using drug-eluting stents in the perioperative period: an update
... more antiplatelet drugs, has many ...of antiplatelet drugs substantially increases the risk of stent thrombosis (ST), myocardial infarction, and cardiac death, and surgery under an altered ...
13
Adverse clinical outcomes associated with double dose clopidogrel compared to the other antiplatelet regimens in patients with coronary artery disease: a systematic review and meta-analysis
... other antiplatelet reg- imens in patients with coronary artery ...dual antiplatelet regimen, the triple antiplatelet regimen, and newer antiplatelet drugs such as prasugrel and ...
11
The REstart or STop Antithrombotics Randomised Trial (RESTART) after stroke due to intracerebral haemorrhage: statistical analysis plan for a randomised controlled trial
... starting antiplatelet drugs versus avoiding antiplatelet drugs on the risk of recurrent symptomatic ICH after spontaneous ...(3) antiplatelet drug(s) that the patient’s physician would ...
8
Interruption to antiplatelet therapy early after acute ischaemic stroke: a nested case control study
... interrupting antiplatelet drugs and cardiovascular risk in patients with recent ischaemic.. We found no evidence for an increased risk of cardiovascular among patients who.[r] ...
24
Antiplatelet drug activity evaluation in patients of acute coronary syndrome in central india: in the scenario of antiplatelet drug resistance
... of antiplatelet targets was initiated (Gasparyan, ...oral antiplatelet drugs as the underlying cause behind these adverse events (Feher, ...prescribed drugs to protect ...antiplatelet ...
5
DRUG UTILIZATION PATTERNS OF STROKE PATIENTS IN A TERTIARY CARE TEACHING HOSPITAL
... population. There were about 8.5% of the people who were taking more than 19 medications. The proportion of subjects who were taking 16 to 18, 13 to 15 and 10 to 12 medications were 16.19%, 14.28% and 26.67%. About ...
9
Antithrombotic drugs do not increase intraoperative blood loss in emergency gastrointestinal surgery: a single-institution propensity score analysis
... antithrombotic drugs had more intraoperative blood loss, higher rate of blood transfusions, higher mortality, longer hospital stay, and a higher rate of surgical site infections than patients not tak- ing ...
10
Evaluation of effects of various drugs on platelet functions using phorbol 12-myristate 13-acetate-induced megakaryocytic human erythroid leukemia cells
... platelets. HEL cells are progenitor cells with the ability to differentiate into megakaryocyte-like cells, and, thus, have served as a useful model for the study of platelet functions. Attempts were made to induce the ...
9
Newer agents in antiplatelet therapy: a review
... new antiplatelet therapies exists as the risk for MI, stroke, and death, remain a persistent problem for individuals suf- fering from cardiovascular ...in antiplatelet therapy, the risk of bleeding is ...
10
ANTIPLATELET THERAPY AND RESISTANCE: A MINI REVIEW
... . Antiplatelet drugs are used to prevent and help in the reversal of platelet aggregation in arterial thrombosis which was the major culprit in the pathology of myocardial infarction and ischaemic ...used ...
8